Overview

Precision Medicine Catapult

World-leading innovation centre for precision medicine
Precision Medicine – Personalising Healthcare

Precision medicine is transforming healthcare - driving treatment and prevention for individuals’ variability in genes, environment and lifestyle. It introduces the UK’s ability to deliver targeted, personalised treatment at an affordable cost. Costs of healthcare in UK are becoming unsustainable - this transformation is essential as the rise in healthcare demand and costs are driving the need to use finite healthcare resources more effectively.

The Precision Medicine Catapult (PMC) will support and accelerate the growth of the sector by enabling development, providing strategic leadership, building a community of expertise and encouraging adoption.

The PMC is currently building the capabilities needed to lead the precision medicine sector in terms of infrastructure, bioinformatics - data, processes and people. With this critical mass, we will ensure that precision medicine becomes a well-regulated, mainstream healthcare solution that truly benefits patients. We will help create a solid foundation for rapid future growth for UK industry.

We are already bringing together key players to shape and direct strategy and priorities, and identify programmes to attract investment and promote growth. We are collaborating with key organisations such as the Medical Research Council, the National Institute for Health Research and our world-leading health research charities to understand how we can exploit the UK’s unique clinical data resources, and create a networked national community of good practice.

We will work to accelerate the uptake of precision medicine and lower barriers to entry to the sector, especially for small and medium-sized enterprises (SMEs). We aim to encourage and enable the adoption of precision medicine by the National Health Service and complementary healthcare systems. We will establish relevant clinical trials and provide access to prototyping and test-bed capabilities for rapid qualification and validation of molecular diagnostic tests.

The UK has more of the components required for a successful precision medicine sector than anywhere else in the world. Our unique role as a neutral convenor will enable us to move quickly to support UK companies in addressing the challenges they face and seizing the opportunities presented by precision medicine, leading to benefits in terms of increased investment, job creation and revenue growth.

Precise Diagnosis | Cost-Effective Treatments | Improved Patient Outcomes